(1) Background: Multiple acute concomitant cerebral infarcts (MACCI) are relatively uncommon. Data regarding the characteristics and outcomes of patients with MACCI are lacking. We, therefore, aimed to characterize the clinical features of MACCI. (2) Methods: Patients with MACCI were identified from a prospective registry of stroke patients admitted to a tertiary teaching center. Patients with an acute single embolic stroke (ASES) involving only one vascular bed served as controls. (3) Results: MACCI was diagnosed in 103 patients who were compared to 150 patients with ASES. MACCI patients were significantly older ( = 0.010), more often had a history of diabetes ( = 0.011) and had lower rates of ischemic heart disease ( = 0.022). On admission, MACCI patients had significantly higher rates of focal signs ( < 0.001), an altered mental state ( < 0.001) and seizures ( = 0.036). The favorable functional outcome was significantly less common in patients with MACCI ( = 0.006). In the multivariable analysis, MACCI was associated with lower chances of achieving favorable outcomes (odds ratio: 0.190, 95% CI: 0.070-0.502). (4) Conclusions: There are important differences in clinical presentation, comorbidities and outcomes between MACCI and ASES. MACCI is less often associated with favorable outcomes and could represent a more severe form of a stroke compared with a single embolic stroke.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299143 | PMC |
http://dx.doi.org/10.3390/jcm12123973 | DOI Listing |
Ann Ital Chir
October 2024
Multidisciplinary Department of Medical-Surgical and Dental Specialties, Plastic Surgery Unit, Università degli Studi della Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Aim: Primary hepatic neuroendocrine carcinomas (PHNECs) are rare tumors with limited understanding and management. Diagnosing and treating these tumors pose significant challenges due to the lack of clinical experience. Surgery is often considered an effective therapeutic strategy for early-stage PHNECs.
View Article and Find Full Text PDFJ Clin Med
June 2023
Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel.
(1) Background: Multiple acute concomitant cerebral infarcts (MACCI) are relatively uncommon. Data regarding the characteristics and outcomes of patients with MACCI are lacking. We, therefore, aimed to characterize the clinical features of MACCI.
View Article and Find Full Text PDFMedicina (Kaunas)
February 2023
Department of Surgery, Policlinico "Umberto I", "Sapienza" University of Rome, Viale del Policlinico 155, 00161 Roma, Italy.
Basosquamous cell carcinoma (BSCC) is a rare malignancy usually arising on sun-exposed areas of the skin. BSCC is described as a rare variant of Basal cell carcinoma (BCC) which shows clinical and microscopic features of both BCC and of Squamous cell carcinoma (SCC). We report the case of a 70-year-old male with a cutaneous lesion of the nipple-areola complex (NAC); to the best of our knowledge, this is the first ever reported patient with BSCC in this area.
View Article and Find Full Text PDFJAMA Netw Open
August 2022
Regeneron Pharmaceuticals Inc, Tarrytown, New York.
Importance: The monoclonal antibody combination of casirivimab and imdevimab reduced viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV) dose in a phase 3 COVID-19 outpatient study. Subcutaneous (SC) and/or lower IV doses should increase accessibility and/or drug supplies for patients.
Objective: To assess the virologic efficacy of casirivimab and imdevimab across different IV and SC doses compared with placebo.
Lancet Infect Dis
October 2022
Regeneron Pharmaceuticals, Tarrytown, NY, USA.
Background: There is an unmet need for COVID-19 prevention in patient populations who have not mounted or are not expected to mount an adequate immune response to complete COVID-19 vaccination. We previously reported that a single subcutaneous 1200 mg dose of the monoclonal antibody combination casirivimab and imdevimab (CAS + IMD) prevented symptomatic SARS-CoV-2 infections by 81·4% in generally healthy household contacts of SARS-CoV-2-infected individuals over a 1-month efficacy assessment period. Here we present additional results, including the 7-month follow-up period (months 2-8), providing additional insights about the potential for efficacy in pre-exposure prophylaxis settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!